BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12426058)

  • 41. [Genetics and environmental factors of Parkinson disease].
    Broussolle E; Thobois S
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S11-23. PubMed ID: 12690660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
    Chen L; Feany MB
    Nat Neurosci; 2005 May; 8(5):657-63. PubMed ID: 15834418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteomic approach to studying Parkinson's disease.
    Zhang J; Goodlett DR
    Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
    Perez RG; Hastings TG
    J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.
    McCormack AL; Mak SK; Shenasa M; Langston WJ; Forno LS; Di Monte DA
    J Neuropathol Exp Neurol; 2008 Aug; 67(8):793-802. PubMed ID: 18648323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
    Corti O; Brice A
    Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
    Sampathu DM; Giasson BI; Pawlyk AC; Trojanowski JQ; Lee VM
    Am J Pathol; 2003 Jul; 163(1):91-100. PubMed ID: 12819014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
    Zhang Y; Dawson VL; Dawson TM
    Neurobiol Dis; 2000 Aug; 7(4):240-50. PubMed ID: 10964596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation.
    McLean PJ; Hyman BT
    Neurosci Lett; 2002 May; 323(3):219-23. PubMed ID: 11959424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.
    Pérez-Sánchez F; Milán M; Buendía P; Cano-Jaimez M; Ambrosio S; Rosenthal A; Fariñas I
    Neuroscience; 2010 May; 167(2):261-76. PubMed ID: 20156526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination.
    Rideout HJ; Stefanis L
    Mol Cell Neurosci; 2002 Oct; 21(2):223-38. PubMed ID: 12401444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alpha-synuclein and Parkinson's disease.
    Golbe LI
    Adv Neurol; 2003; 91():165-74. PubMed ID: 12442675
    [No Abstract]   [Full Text] [Related]  

  • 57. Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
    Rekha KR; Selvakumar GP; Santha K; Inmozhi Sivakamasundari R
    Biochem Biophys Res Commun; 2013 Nov; 440(4):664-70. PubMed ID: 24103762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
    Koo JH; Jang YC; Hwang DJ; Um HS; Lee NH; Jung JH; Cho JY
    Neuroscience; 2017 Jul; 356():102-113. PubMed ID: 28527958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
    Zhou W; Hurlbert MS; Schaack J; Prasad KN; Freed CR
    Brain Res; 2000 Jun; 866(1-2):33-43. PubMed ID: 10825478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons.
    Wilson CA; Murphy DD; Giasson BI; Zhang B; Trojanowski JQ; Lee VM
    J Cell Biol; 2004 May; 165(3):335-46. PubMed ID: 15123735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.